Tick-borne infections in children: Epidemiology, clinical manifestations, and optimal management strategies

Pediatric Drugs

Volumn 7, Issue 3, 2005, Pages 163-176

  Buckingham, Steven C ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ATOVAQUONE; AZITHROMYCIN; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; DIETHYLTOLUAMIDE; DOXYCYCLINE; ERYTHROMYCIN; HYPERIMMUNE GLOBULIN; JOSAMYCIN; QUININE; RIBAVIRIN; SULFONAMIDE; TETRACYCLINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY TITER; ARACHNID; BABESIOSIS; BORRELIA BURGDORFERI; BORRELIA INFECTION; BOUTONNEUSE FEVER; CLINICAL FEATURE; COLORADO TICK FEVER; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE SEVERITY; EHRLICHIOSIS; EXCHANGE BLOOD TRANSFUSION; FRANCISELLA TULARENSIS; GEOGRAPHIC DISTRIBUTION; HEMORRHAGIC FEVER; HUMAN; IMMUNOFLUORESCENCE TEST; INCUBATION TIME; INFECTION PREVENTION; INFECTION RATE; LABORATORY TEST; LYME DISEASE; MITE; NAIRO VIRUS; PARASITE SERODIAGNOSIS; PARASITE VECTOR; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RICKETTSIOSIS; ROCKY MOUNTAIN SPOTTED FEVER; SCORPION; SIDE EFFECT; SPIDER; TICK BITE; TICK BORNE DISEASE; TICK BORNE ENCEPHALITIS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; TOOTH COLOR; TULAREMIA; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; BABESIOSIS; EHRLICHIOSIS; HUMANS; LYME DISEASE; ROCKY MOUNTAIN SPOTTED FEVER; TICK-BORNE DISEASES; TICKS; TULAREMIA; VIRUS DISEASES;

EID: 22644436812     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200507030-00003     Document Type: Review

References (96)

1. Sonenshine DE, Azad AF. Ticks and mites in disease transmission. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 992-1003
2. Spach DH, Liles WC, Campbell GL, et al. Tick-borne diseases in the United States. N Engl J Med 1993; 329: 936-47
3. American Academy of Pediatrics. Prevention of tick-borne infections. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 186-7
4. McDade JE, Newhouse VF. Natural history of Rickettsia rickettsii. Annu Rev Microbiol 1986; 40: 287-309
5. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995; 52: 405-13
6. Treadwell TA, Holman RC, Clarke MJ, et al. Rocky Mountain spotted fever in the United States, 1993-1996. Am J Trop Med Hyg 2000; 63: 21-6
7. Brouqui P. Tick-borne rickettsioses of the eastern hemisphere. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 438-41
8. Raoult D, Roux V. Rickettsioses as paradigms of new or emerging infectious diseases. Clin Microbiol Rev 1997; 10: 694-719
9. Strickland GT, Olson JG. Ehrlichiosis. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 445-8
10. Jacobs RF. Human monocytic ehrlichiosis: similar to Rocky Mountain spotted fever but different. Pediatr Ann 2002; 31: 180-4
11. Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001; 51: 2145-65
12. Steere AC. Lyme disease. N Engl J Med 1989; 321: 586-96
13. Stechenberg BW. Borrelia (Lyme disease). In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Philadelphia (PA): WB Saunders, 1998: 1522-7
14. Kirkland KB, Klimko TB, Meriwether RA, et al. Erythema migrans-like rash illness at a camp in North Carolina: a new tick-borne disease? Arch Intern Med 1997; 157: 2635-41
15. Campbell GL, Paul WS, Schriefer ME, et al. Epidemiologic and diagnostic studies of patients with suspected early Lyme disease, Missouri, 1990-1993. J Infect Dis 1995; 172: 470-80
16. Masters E, Granter S, Duray P, et al. Physician-diagnosed erythema migrans and erythema migrans-like rashes following Lone Star tick bites. Arch Dermatol 1998; 134: 955-60
17. Felz MW, Chandler Jr FW, Oliver Jr JH, et al. Solitary erythema migrans in Georgia and South Carolina. Arch Dermatol 1999; 135: 1317-26
18. James AM, Liveris D, Wormser GP, et al. Borrelia lonestari infection after a bite by an Amblyomma americanum tick. J Infect Dis 2001; 183: 1810-4
19. American Academy of Pediatrics. Borrelia (relapsing fever). In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 220-2
20. Butler T. Relapsing fever. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 448-52
21. Parola P, Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat [published erratum appears in Clin Infect Dis 2001; 33: 749]. Clin Infect Dis 2001; 32: 897-928
22. American Academy of Pediatrics. Tularemia. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 666-7
23. Bryant KA. Tularemia: lymphadenitis with a twist. Pediatr Ann 2002; 31: 187-90
24. American Academy of Pediatrics. Babesiosis. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 211-2
25. Herwaldt BL. Babesiosis. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 688-90
26. Lantos PM, Krause PJ. Babesiosis: similar to malaria but different. Pediatr Ann 2002; 31: 192-7
27. McCormick JB, Fisher-Hoch SP. Crimean-Congo hemorrhagic fever. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 284-7
28. Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Res 2003; 57: 129-46
29. Aebi C, Tsai TF. Tick-borne encephalitis. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Philadelphia (PA): WB Saunders, 1998: 2003-8
30. Klasco R. Colorado tick fever. Med Clin North Am 2002; 86: 435-40
31. Needham GR. Evaluation of five popular methods for tick removal. Pediatrics 1985; 75: 997-1002
32. Insect repellants. Med Lett Drugs Ther 2003; 45: 41-2
33. Fradin MS. Mosquitoes and mosquito repellants: a clinician's guide. Ann Intern Med 1998; 128: 931-40
34. American Academy of Pediatrics. Follow safety precautions when using DEET on children [online]. Available from http://www.aap.org/family/wnv-jun03.htm [Accessed 2003 Oct 23]
35. Rolain JM, Maurin M, Vestris G, et al. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 1998; 42: 1537-41
36. Bradford WD, Hawkins HK. Rocky Mountain spotted fever in childhood. Am J Dis Child 1977; 131: 1228-32
37. Helmick CG, Bernard KW, D'Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984; 150: 480-8
38. Buckingham SC. Rocky Mountain spotted fever: a review for the pediatrician. Pediatr Ann 2002; 31: 163-8
39. American Academy of Pediatrics. Rocky Mountain spotted fever. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 532-4
40. Hattwick MAW, Retailliau H, O'Brien RJ, et al. Fatal Rocky Mountain spotted fever. JAMA 1978; 240: 1499-503
41. Holman RC, Paddock CD, Curns AT, et al. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001; 184: 1437-44
42. Smith M, Unkel JH, Fenton SJ, et al. The use of tetracyclines in pediatric patients. J Pediatr Pharmacol Ther 2001; 6: 66-71
43. Lochary ME, Lockhart PB, Williams WT. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998; 17: 429-31
44. Forti G, Benincori C. Doxycycline and the teeth. Lancet 1969; I: 782-3
45. Anton E, Font B, Munoz T, et al. Clinical and laboratory characteristics of 144 patients with Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 2003; 22: 126-8
46. Font-Creus B, Bella-Cueto F, Espejo-Arenas E, et al. Mediterranean spotted fever: a cooperative study of 227 cases. Rev Infect Dis 1985; 7: 635-42
47. Raoult D, Weiller PJ, Chagnon A, et al. Mediterranean spotted fever: clinical, laboratory and epidemiological features of 199 cases. Am J Trop Med Hyg 1986; 35: 845-50
48. Bella-Cueto F, Font-Creus B, Segura-Porta F, et al. Comparative, randomized trial of one-day doxycycline versus 10-day tetracycline therapy for Mediterranean spotted fever. J Infect Dis 1987; 155: 1056-8
49. Ruiz Beltran R, Herrero Herrero JI. Evaluation of ciprofloxacin and doxycycline in the treatment of Mediterranean spotted fever. Eur J Clin Microbiol Infect Dis 1992; 11: 427-31
50. Cascio A, Dones P, Romano A, et al. Clinical and laboratory findings of boutonneuse fever in Sicilian children. Eur J Pediatr 1998; 157: 482-6
51. Munoz-Espin T, Lopez-Pares P, Espejo-Arenas E, et al. Erythromycin versus tetracycline for treatment of Mediterranean spotted fever. Arch Dis Child 1986; 61: 1027-9
52. Bella F, Font B, Uriz S, et al. Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever. Antimicrob Agents Chemother 1990; 34: 937-8
53. Meloni G, Meloni T. Azithromycin vs. doxycycline for Mediterranean spotted fever. Pediatr Infect Dis J 1996; 15: 1042-4
54. Cascio A, Colomba C, Antinori S, et al. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis 2002; 34: 154-8
55. Ruiz Beltran R, Herrero Herrero JI. Deleterious effect of trimethoprim-sulfamethoxazole in Mediterranean spotted fever. Antimicrob Agents Chemother 1992; 36: 1342-3
56. Raoult D, Lakos A, Fenollar F, et al. Spotless rickettsiosis caused by Rickettsia slovaca and associated with Dermacentor ticks. Clin Infect Dis 2002; 34: 1331-6
57. Maeda K, Markowitz N, Hawley RC, et al. Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987; 316: 853-6
58. Fishbein DB, Dawson JE, Robinson LE. Human ehrlichiosis in the United States, 1985 to 1990. Ann Intern Med 1994; 120: 736-43
59. Jacobs RF, Schutze GE. Ehrlichiosis in children. J Pediatr 1997; 131: 184-92
60. American Academy of Pediatrics. Ehrlichiosis. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 266-9
61. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother 1992; 36: 2799-803
62. Fichtenbaum CJ, Peterson LR, Weil GJ. Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome. Am J Med 1993; 95: 351-7
63. Patel RG, Byrd MA. Near fatal acute respiratory distress syndrome in a patient with human ehrlichiosis. South Med J 1999; 92: 333-5
64. Peters TR, Edwards KM, Standaert SM. Severe ehrlichiosis in an adolescent taking trimethoprim-sulfamethoxazole. Pediatr Infect Dis J 2000; 19: 170-2
65. Brantley RK. Trimethoprim-sulfamethoxazole and fulminant ehrlichiosis [letter]. Pediatr Infect Dis J 2001; 20: 231
66. Bakken JS, Dumler JS, Chen SM, et al. Human granulocytic ehrlichiosis in the upper midwest United States: a new species emerging? JAMA 1994; 272: 212-8
67. Bakken JS, Krueth J, Wilson-Nordskog C, et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275: 199-205
68. Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 2003; 47: 413-5
69. Buitrago MI, Ijdo JW, Rinaudo P, et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis 1998; 27: 213-5
70. Buller RS, Arens M, Hmiel SP. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999; 341: 148-55
71. Storch GA. New developments in tick-borne infections. Pediatr Ann 2002; 31: 200-4
72. American Academy of Pediatrics. Lyme disease. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 407-11
73. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease: the Infectious Diseases Society of America. Clin Infect Dis 2000; 31 (1 Suppl.): 1-14
74. Terekhova D, Sartakova ML, Wormser GP, et al. Erythromycin resistance in Borrelia burgdorferi. Antimicrob Agents Chemother 2002; 46: 3637-40
75. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996; 124: 785-91
76. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics 2002; 109: 1173-7
77. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92
78. Patel R, Grogg KL, Edwards WD, et al. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 2000; 31: 1107-9
79. Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med 2003; 348: 2424-30
80. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxy-cycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79-84
81. Dworkin MS, Anderson DE, Schwan TG, et al. Tick-borne relapsing fever in the northwestern United States and southwestern Canada. Clin Infect Dis 1998; 26: 122-31
82. Stewart SJ. Francisella. In: Murray PR, editor. Manual of clinical microbiology. Washington (DC): ASM Press, 1995: 545-8
83. Enderlin G, Morales L, Jacobs RF, et al. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19: 42-7
84. Cross JT, Schutze GE, Jacobs RF. Treatment of tularemia with gentamicin in pediatric patients. Pediatr Infect Dis J 1995; 14: 151-2
85. Johansson A, Berglund L, Sjostedt A, et al. Ciprofloxacin for treatment of tularemia [letter]. Clin Infect Dis 2001; 33: 267-8
86. Johansson A, Berglund L, Gothefors L, et al. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19: 449-53
87. Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clin Infect Dis 1999; 29: 922-4
88. American Academy of Pediatrics. Fluroquinolones. In: Pickering LK, editor. 2003 Red Book: Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village (IL): American Academy of Pediatrics, 2003: 693-4
89. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000; 343: 1454-8
90. Raoult D, Soulayrol L, Toga B, et al. Babesiosis, pentamidine, and cotrimoxazole [letter]. Ann Intern Med 1987; 107: 944
91. Fisher-Hoch SP, Khan JK, Rehman S, et al. Crimean-Congo hemorrhagic fever treated with oral ribavirin. Lancet 1995; 346: 472-5
92. Van de Wal BW, Joubert JR, Van Eeden PJ, et al. A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg Hospital: IV. Preventive and prophylactic measures. S Afr Med J 1985; 68: 729-32
93. Mardani M, Jahromi MK, Naieni KH, et al. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36: 1613-8
94. Tsai T. Kyasanur forest disease. In: Strickland GT, editor. Hunter's tropical medicine. 8th ed. Philadelphia (PA): WB Saunders, 2000: 293-5
95. Crance JM, Scaramozzino N, Jouan A, et al. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003; 58: 73-9
96. Smee DF, Sidwell RW, Clark SM, et al. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances. Antimicrob Agents Chemother 1981; 20: 533-8